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Conclusions: In the United States, tobacco control is estimated to
have been associated with avoidance of 8 million premature deaths and an
estimated extension of mean life span of 19 to 20 years.
Summary: January 2014 marked the 50th anniversary of the ﬁrst
Surgeon General’s report on smoking and health (Surgeon General’s
Advisory Committee on Smoking and Health [1964] http://proﬁles.
nlm.nih.gov/NN/B/B/M/Q/, accessed December 13, 2013.) What
followed were efforts by governments, voluntary organizations, and
the private sector to provide education on smoking dangers. Also fol-
lowed were increases in cigarette taxes, smoke-free air laws, antismoking
media campaigns, marketing and sales restrictions on tobacco com-
panies, lawsuits, and a greater focus on smoking-cessation treatment
programs. A recent report also estimates many individuals in the United
States gained additional years of life from 1964 through 2012, with this
a direct result of tobacco control-inﬂuenced decisions to quit smoking
or never start smoking (Warner KE et al, Am J Public Health
2014;104:83-9). It is also estimated that >800,000 lung cancer deaths
have been avoided between 1975 and 2000 as a result of tobacco control
(Moolgavkar SH et al, J Natl Cancer Inst 2012;104:541-8). The objec-
tive of this current report was to model reductions in smoking-related
mortality associated with implementation of tobacco controls since
1964. Smoking histories for individual birth cohorts that would have
occurred under likely scenarios had tobacco control never emerged
were estimated. National mortality rates and mortality rate ratio esti-
mates from analytic studies of the effect of smoking on mortality yielded
death rates by smoking status. Actual smoking-related mortality from
1964 through 2012 was compared with estimated mortality under no
tobacco control, including a likely scenario (primary counterfactual)
and upper and lower bounds that would capture plausible alternatives.
Smoking histories were obtained from National Health Interview Sur-
veys for the United States adult population from 1964 through 2012.
The number of premature deaths avoided and years of life saved were
primary outcomes. Change in life expectancy at age 40 years associated
with change in cigarette smoking exposure constituted another measure
of overall health outcome. From 1964 to 2012, an estimated 17.7
million deaths were related to smoking. An estimated 8.0 million (cred-
ible range [CR], 7.4-8.3, million for the lower and upper tobacco con-
trol counterfactuals, respectively) fewer premature smoking-related
deaths than what would have occurred under the alternatives and thus
associated with tobacco control (5.3 [CR, 4.8-5.5] million men and
2.7 [CR, 2.5-2.7] million women). This resulted in an estimated 157
million life-years (CR, 139-165 million life-years) saved, a mean of
19.6 years for each beneﬁciary (111 [CR, 97-117] million life-years
for men, 46 [CR, 42-48 ] million life-years for women). During this
time, estimated life expectancy at age 40 increased 7.8 years for men
and 5.4 years for women, of which tobacco control is associated with
2.3 years (CR, 1.8-2.5 years) for men (30% [CR, 23%-32%] of the in-
crease) and 1.6 years (CR, 1.4-1.7 years) for women (29% [CR, 25%-
32%] of the increase).
Comment: Since the Surgeon General Report of 1964 and the
implementation of tobacco controls, the fact that an estimated 8 million
U.S. individuals have had their lives extended by these tobacco controls
argues that tobacco control has in a sense been a great public health suc-
cess story. Unfortunately, however, nearly 50 years later, still a ﬁfth of
U.S. adults continue to smoke, and smoking continues to claim hun-
dreds of thousands of lives annually. In fact, an additional article in
the same issue of the Journal of the American Medical Association, in
which this article appeared, indicates that since 1980, although there
have been large reductions in the estimated percentage prevalence of
daily smoking globally for men and women, population growth means
the actual number of smokers has in fact increased signiﬁcantly. Tobacco
therefore still remains a threat, and perhaps a potentially increasing
threat, to the health of the world’s population (Ng M et al, JAMA
2014;311:183-92).1174A Clinical Rule (Sex, Contralateral Occlusion, Age, and Restenosis)
to Select Patients for Stenting Versus Carotid Endarterectomy:
Systematic Review of Observational Studies With Validation in
Randomized Trials
Touzé E, Trinquart L, Felgueiras R, et al. Stroke 2013;44:3394-400.
Conclusions: A clinical prediction rule based on sex, contralateral ca-
rotid occlusion, age, and restenosis may be potentially useful in identifying
patients in whom carotid artery stenting (CAS) is not inferior with respect to
carotid endarterectomy (CEA) for risk of perioperative stroke or death.
Summary: Randomized trials strongly suggest CAS is associated with
higher procedural risk of stroke than CEA in patients with symptomatic ste-
nosis (Bonati LH et al, Cochrane Database Syst Rev 2012;9:CD000515;
and Brott TG et al, N Engl J Med 2010;363:11-23). However, additional
data suggest that risk of stroke may be similar for CAS and CEA after the
periprocedural period (Mas JL et al, Lancet Neurol 2008;7:885-92; and
Eckstein HH et al, Lancet Neurol 2008;7:893-902). The authors of the
current report have also previously demonstrated that meta-analysis of risk
associations from a compilation of large observational studies can provide
potentially reliable and consistent data on clinical characteristics associated
with procedural risk of CEA and CAS (Bonati LH et al, Lancet
2010;376:1062-73). In this study, the authors sought to derive a simple
clinical risk rule to enable clinicians to potentially choose between CAS
and CEA in the treatment of patients with symptomatic carotid artery ste-
nosis. This was a systematic review of observational studies of procedural
risk of CEA or CAS, which extracted data on nine predeﬁned risk factors:
age, contralateral carotid occlusion, coronary artery disease, diabetes melli-
tus, sex, hypertension, peripheral artery disease, and type and side of steno-
sis. Pooled relative risks of procedural stroke or death were then calculated.
Factors with differential effects on the risk of CAS vs CEA were identiﬁed by
interaction tests and used to derive a rule for patient selection. The rule was
then tested using individual patient data from randomized trials of CAS vs
CEA from The Carotid Stenting Trialists’ Collaboration.
The authors identiﬁed 170 studies for inclusion in their analysis. Two
independent reviewers used titles and abstracts to assess the eligibility of
studies. Final selection for inclusion in the analysis was made after reviewing
full-text articles. Ultimately, 170 studies (227 articles, >70,000 patients)
provided data for one or more of the nine potential risk factors. There
were 115 studies (149 articles) relating to CEA and 68 studies (83 articles)
relating to CAS, with some studies related to both CEA and CAS. Analysis
indicated patients with contralateral occlusion or restenosis and women
aged <75 years were at relatively low risk for CAS (SCAR-negative), with
all others being high risk (SCAR-positive). In the Carotid Stenting Trialists’
Collaboration validation portion of the study, there were 3049 patients, and
694 (23%) were SCAR-negative. The pooled relative risk of procedural
stroke and death with CAS vs CEA was 0.93 (0.49-1.77; P ¼ .83) in
SCAR-negative patients and 2.41 (1.68-3.45; P < .0001) in SCAR-positive
patients (P ¼ .05 for interaction).
Comment: The data have several limitations. First, most patients with
recurrent carotid stenosis likely do not need treatment. In addition, the au-
thors were not able to stratify for type of protection devices used with CAS,
and data were not available concerning anatomic variables, such as type of
aortic arch, angulation of the carotid artery, severe calciﬁcation of the ca-
rotid bifurcation, or plaque composition, that may have signiﬁcant inﬂuence
on periprocedural risk of CAS. From a simplistic point of view, one can
make the observation that there was no score that indicated CAS was better
than CEA and that the large majority of patients were best treated with CEA
over CAS based on the clinical score derived. It therefore appears, as we
already knew, that in the large majority of clinical circumstances, CEA still
seems preferable to CAS.
A Pragmatic View of the New Cholesterol Treatment Guidelines
Keaney JF, Curfman GD, Jarcho JA. N Engl J Med 2014;370:275-8.
Conclusions: The new cholesterol treatment guidelines represent a
substantial departure from previous recommendations.
Summary: This short article summarized updated guidelines for the
treatment of high blood cholesterol levels that were released in November
